This is a news story, published by CNBC, that relates primarily to Novo Nordisk's news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
blockbuster Wegovy weight loss drug. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest weight loss drug candidates news, Novo Nordisk news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
obesity medication marketCNBC
•84% Informative
Novo Nordisk's Wegovy weight loss drug has received backing from the European Union's medical regulator to expand its use to reduce the rise of serious heart events in overweight and obese adults.
The European Medical Agency has adopted a "positive opinion" on the label expansion, opening the door to further applications for the drug.
The Danish pharmaceutical giant said it expects to implement the label update within a month .
VR Score
89
Informative language
95
Neutral language
16
Article tone
formal
Language
English
Language complexity
74
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links